- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06136065 | 68 Gallium-Fibroblast Activating Protein Inhibitors-46 Positron Emission Tomography - Computerized Tomography for Molecular Assessment of Fibroblast Activation and Risk Assessment in Solid Tumors(FAPI) | unknown | Phase 2 | 100 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT04092673 | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies(Zotatifin) | unknown | Phase 1 / Phase 2 | 30 | Effector Therapeutics |
| 1 |
| May 21, 2024 |
| clinicaltrials |
| NCT04983810 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma | unknown | Phase 1 / Phase 2 | 330 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 3 | Jan 25, 2024 | clinicaltrials |
| NCT06056323 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 71 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT03382340 | IMX-110 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 70 | Immix Biopharma Australia Pty LtdINDUSTRY | 2 | Sep 28, 2023 | clinicaltrials |
| NCT05986981 | MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05322720 | HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy | unknown | Phase 2 | 50 | Taizhou EOC Pharma Co., Ltd.INDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT03160833 | A Study of HMPL-453 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 33 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT03030001 | PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies | unknown | Phase 1 / Phase 2 | 40 | Ningbo Cancer HospitalINDUSTRY | 1 | Jan 24, 2017 | clinicaltrials |
| NCT01764087 | A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | May 18, 2015 | clinicaltrials |
| NCT00002482 | Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer | unknown | Phase 1 / Phase 2 | — | St. Vincent Medical Center - Los AngelesOTHER | 1 | Nov 6, 2013 | clinicaltrials |
| NCT00004063 | Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer | unknown | Phase 1 / Phase 2 | 30 | The University of Texas Health Science Center, HoustonOTHER | 1 | Apr 30, 2009 | clinicaltrials |
| NCT00274859 | Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Cancer | unknown | Phase 2 | 45 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 24, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Jun 4, 2024source: clinicaltrials